Eli Lilly (LLY)
(Delayed Data from NYSE)
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $775.43 -0.95 (-0.12%) 5:06 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $775.43 -0.95 (-0.12%) 5:06 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum
by Zacks Equity Research
Eli Lilly, Thermo Fisher Scientific, TotalEnergies, Amgen and Marathon Petroleum have been included in this Analyst Blog.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $331.60 in the latest trading session, marking a +1.44% move from the prior day.
Top Stock Reports for Eli Lilly, Thermo Fisher & TotalEnergies
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Thermo Fisher Scientific Inc. (TMO), and TotalEnergies SE (TTE).
Strength Seen in H Lundbeck AS (HLUYY): Can Its 11.2% Jump Turn into More Strength?
by Zacks Equity Research
H Lundbeck AS (HLUYY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $331.07 in the latest trading session, marking a +0.18% move from the prior day.
Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
by Zacks Equity Research
Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.
Should Invesco Dynamic Large Cap Growth ETF (PWB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWB
Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's
by Zacks Equity Research
The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $327.18, moving +0.76% from the previous trading session.
LabCorp (LH) to Strengthen Laboratory Footprint in Japan
by Zacks Equity Research
LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.
The Zacks Analyst Blog Highlights Meta Platforms, Eli Lilly, The Home Depot, The Boeing Company, Vale
by Zacks Equity Research
Meta Platforms, Eli Lilly, The Home Depot, The Boeing Company, Vale are part of Zacks top Analyst Blog.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
Top Analyst Reports for Meta Platforms, Eli Lilly & Home Depot
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Eli Lilly and Company (LLY), and The Home Depot, Inc. (HD).
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $327.27, marking a +0.51% move from the previous day.
Radius (RDUS) to Go Private With $890M Deal, Shares Gain
by Zacks Equity Research
Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug
by Zacks Equity Research
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.
LabCorp (LH) Partners HealthVerity to Grow in Drug Development
by Zacks Equity Research
According to LabCorp (LH), this partnership is expected to broaden its comprehensive, end-to-end drug development and clinical trial programs.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $290.90, marking a +0.98% move from the previous day.
LabCorp (LH) Gets FDA Nod for VirSeq SARS-CoV-2 NGS Test
by Zacks Equity Research
LabCorp's (LH) VirSeq SARS-CoV-2 NGS Test can detect specific SARS-CoV-2 strains to help health care providers make appropriate patient treatment decisions.
The Zacks Analyst Blog Highlights Lilly, Merck, Roche, Pfizer and Moderna
by Zacks Equity Research
Lilly, Merck, Roche, Pfizer and Moderna have been included in this Analyst Blog.
Pharma Stock Roundup: FDA Panel Nod for PFE, MRNA Young Kids' COVID Jabs & More
by Kinjel Shah
FDA panel recommends the use of PFE, MRNA COVID vaccine in kids under five. LLY's Alzheimer's candidate fails to show clinical benefit in study. FDA approves expanded use of LLY's Olumiant.
Roche Alzheimer's Candidate Failure Hurts Lilly, Biogen
by Kinjel Shah
Eli Lilly (LLY) and Biogen's (BIIB) Alzheimer's candidates, anti-amyloid beta antibodies, are in late-stage development and are expected to be launched in a few months.
Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata
by Zacks Equity Research
Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.